Showing results (431-440 of 464) with videos related to

Sort By:
Pageof 47
Cancer Research Communications|July 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung CancerTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Translational Lung Cancer Research|June 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expressionHayato Kawachi, Tae Hata, Tadaaki Yamada, et al.
Cancer Treatment and Research Communications|July 4, 2024
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancerKanako Sakaeda, Koji Kurose, Yuki Matsumura, et al.
Cancer Science|July 9, 2020
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world dataKentaro Ito, Kenta Murotani, Akihito Kubo, et al.
Clinical Lung Cancer|January 26, 2025
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort StudyTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Thoracic Cancer|September 7, 2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO studyHiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, et al.
JTO Clinical and Research Reports|May 30, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in JapanYasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, et al.
Cell Reports|May 18, 2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLCHirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 4, 2015
[A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib]Yutaka Takeda, Shin Nakahira, Yoshiteru Katsura, et al.
Cancer Research and Treatment|November 1, 2024
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective StudyNaoya Nishioka, Tae Hata, Tadaaki Yamada, et al.
Pageof 47